Children’s ZYRTEC® 10 mg makes a significant impact on allergy symptoms1

In patients ages 6 to 12 years with seasonal allergic rhinitis (SAR), Children’s ZYRTEC® provides a powerful symptom response1

Studies show 37% and 19% of children demonstrated ≥50% improvement from baseline SAR symptoms over 2 weeks.1

Randomized, placebo-controlled studies of children aged 6 to 12 years with SAR during a 2-week period. Primary endpoint was the change in total symptom score complex from baseline.

*Significant vs placebo.

†ZYRTEC® 10 mg vs placebo ratio at ≥50% reduction is 1.88-fold in Study 1 and 1.42-fold in Study 2.

Reference: 1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

Learn more about Children's ZYRTEC®

Children's ZYRTEC® allergy products Children's ZYRTEC® allergy products

View Children's ZYRTEC® tolerability profile

Children play sword-fighting Children play sword-fighting

Caregiver Brochure

Help educate children and caregivers about allergies with an educational brochure and storybook.

Children's ZYRTEC® patient educational brochure and storybook Children's ZYRTEC® patient educational brochure and storybook